Navigation Links
VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
Date:5/31/2008

athy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with few or no risk factors for decreased left ventricular ejection fraction. There have been rare reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syndrome in patients receiving VELCADE. Some of these events have been fatal. A higher proportion of these events have been reported in Japan. There have been rare reports of Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in patients receiving VELCADE. RPLS is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. VELCADE is associated with thrombocytopenia and neutropenia. There have been reports of gastrointestinal and intracerebral hemorrhage in association with VELCADE. Transfusions may be considered. Complete blood counts (CBC) should be frequently monitored during treatment with VELCADE. Rare cases of acute liver failure have been reported in patients receiving multiple concomitant medications and with serious underlying medical conditions.

Integrated Safety Data: Safety data from Phase II and III studies of single-agent VELCADE 1.3 mg/m2/dose twice weekly for 2 weeks followed by a 10-day rest period in 1163 patients with multiple myeloma (N=1008) and mantle cell lymphoma (N=155) were integrated and tabulated. In these studies, the safety profile of VELCADE was similar in patients with multiple myeloma and mantle cell lymphoma. In the integrated analysis, the most commonly reported adverse events were asthenic conditions (including fatigue, malaise, and weakness) (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuro
'/>"/>

SOURCE Millennium Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
2. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
3. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
4. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
5. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
6. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
7. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
8. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
11. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  RESMED INC. (NYSE: ... quarter and fiscal year ended June 30, 2014 results on ... market close. A press release with ResMed,s results will be ... will host a webcast to discuss operating results and future ... at 1:30 p.m. US Pacific Time and the live webcast ...
(Date:7/10/2014)... , July 10, 2014  Decision Resources Group ... infectious disease (ID) specialists are willing to prescribe ... (oritavancin) for use as OPAT, approximately two-thirds of ... agents to their hospital inpatients. However, our findings ... patients are initiated on OPAT following hospital discharge, ...
(Date:1/15/2014)... ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry Report, 2013-2015" research ... http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting from aging of ... orthopedic instrument industry has seen rapid development ... 3.28 billion yuan in 2006 to 9.85 billion yuan ...
Breaking Medicine Technology:ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3
... Six years ago, before smartphones were a veritable cornerstone ... Michigan joined an initiative to begin using similar handheld ... prescribe medications for their patients.  Today, ... (SEMI) reports that more than 7,500 physicians in the ...
... 28, 2012 Bionovo, Inc. (OTCQB: BNVI), a pharmaceutical company ... effective treatments for women,s health and cancer, announced today ... recommended that the Phase 3 trial of Menerba (MF101) ... its clinical safety and tolerability data. Menerba is Bionovo,s ...
Cached Medicine Technology:Entering its Prime: Southeast Michigan ePrescribing Initiative, One of the Nation's Longest Running ePrescribing Programs, Increases Enrollment by 33 Percent; Kicks off Seventh Year 2Entering its Prime: Southeast Michigan ePrescribing Initiative, One of the Nation's Longest Running ePrescribing Programs, Increases Enrollment by 33 Percent; Kicks off Seventh Year 3Entering its Prime: Southeast Michigan ePrescribing Initiative, One of the Nation's Longest Running ePrescribing Programs, Increases Enrollment by 33 Percent; Kicks off Seventh Year 4Entering its Prime: Southeast Michigan ePrescribing Initiative, One of the Nation's Longest Running ePrescribing Programs, Increases Enrollment by 33 Percent; Kicks off Seventh Year 5Entering its Prime: Southeast Michigan ePrescribing Initiative, One of the Nation's Longest Running ePrescribing Programs, Increases Enrollment by 33 Percent; Kicks off Seventh Year 6Entering its Prime: Southeast Michigan ePrescribing Initiative, One of the Nation's Longest Running ePrescribing Programs, Increases Enrollment by 33 Percent; Kicks off Seventh Year 7Bionovo's Independent Data Safety Monitoring Board Recommends Continuation of Phase 3 Study for Menerba™ 2Bionovo's Independent Data Safety Monitoring Board Recommends Continuation of Phase 3 Study for Menerba™ 3Bionovo's Independent Data Safety Monitoring Board Recommends Continuation of Phase 3 Study for Menerba™ 4
(Date:7/10/2014)... health concerns in the United States, with 32 percent ... 2012. As health problems such as childhood obesity grow, ... the problem. , A new study, led by Jenine ... at Washington University in St. Louis, examined the use ... conversations about the issue of overweight kids. , The ...
(Date:7/10/2014)... Human Services (HHS) has announced a three-year grant to ... totaling $4.7 million to support a new national model ... , Titled "Evidence-Conformant Oncology Care," the project will ... care for adult cancer patients with late-stage disease, significant ... , "We believe that the best cancer ...
(Date:7/10/2014)... Up to 70% of Parkinson,s disease (PD) ... quality of life. Some patients have disturbed sleep/wake ... asleep, while other patients may be subject to ... extreme, PD patients may exhibit REM-sleep behavior disorder ... re-enactment, even before motor symptoms appear. A review ...
(Date:7/10/2014)... at the University of Huddersfield could help to improve ... food products such as butter, mayonnaise, yoghurt and ... an international profile for her work. , Katerina gained ... the University and now she has embarked on research ... Vassilis Kontogiorgos, she is investigating the potential of carbohydrates ...
(Date:7/10/2014)... identifying the clinical indicators most strongly associated with concussion ... developing evidence-based guidelines for concussion diagnosis, prognosis, and treatment, ... Neurosurgery , official journal of the ... by Lippincott Williams & Wilkins , a part ... Based on analysis of the best available research data, ...
Breaking Medicine News(10 mins):Health News:Study looks at how Twitter can be used to address specific health issues 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3Health News:Sleep disturbances, common in Parkinson's disease, can be early indicator of disease onset 2Health News:World interest in research work on the benefits of the Okra plant 2Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3
... typically ones headed by a medical doctor rather than a manager. ... makes a good hospital. The research, to be published in ... first of its kind. Its conclusions run counter to a ... -- not those with a medical degree -- at the helm ...
... By pairing an award-winning remote-detection version of NMR/MRI ... designed for microfluidic chips, researchers with the U.S. ... (Berkeley Lab) have opened the door to a ... that would be impractical if not impossible with ...
... , WEDNESDAY, July 6 (HealthDay News) -- Brief, voluntary ... reduce their use of the drug, according to a new ... to these discussions about marijuana was more effective than merely ... drug. Marijuana is a common drug choice for teens ...
... form of brain tumor in people. Research published in ... Design offers a novel way to determine what ... to form. Understanding the problems at the molecular level ... in glioblastoma and ultimately lead to treatments or even ...
... , WEDNESDAY, July 6 (HealthDay News) -- Being satisfied with ... the finding of a new study that included almost 8,000 ... their satisfaction in seven areas of their lives: romantic relationships, ... self. Over a follow-up period of about six years, ...
... ablative radiotherapy and improvements in surgical care in early-stage ... elderly Dutch patients, according to a population-based study presented ... Amsterdam, hosted by the International Association for the Study ... Dutch non-small cell lung cancer (NSCLC) patients increased by ...
Cached Medicine News:Health News:The best hospitals are run by physicians 2Health News:Berkeley Lab researchers apply NMR/MRI to microfluidic chromatography 2Health News:Berkeley Lab researchers apply NMR/MRI to microfluidic chromatography 3Health News:Berkeley Lab researchers apply NMR/MRI to microfluidic chromatography 4Health News:Talking to Teens May Help Them Cut Back on Pot Smoking 2Health News:What causes brain cancer? 2Health News:Elderly Dutch lung patients' survival improved by new treatment options between 2003-2009 2
... interoperative placement to stent the ... and continent urinary diversions. Supplied ... for one-time use. CAUTION: Periodic ... not remain indwelling more than ...
... a device that provides effective cutting and simultaneous ... to provide the urologist with the same touch ... the approximate speed and the same ease of ... but with a 45% greater zone of ...
Used for stone manipulation and removal in the renal pelvis under direct vision. Supplied sterile in peel-open packages. Intended for one-time use....
Used for stone manipulation and removal in the renal pelvis under direct vision. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: